{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:38:42Z","timestamp":1793205522753,"version":"4.5.0"},"reference-count":19,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2026,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Low-intensity pulsed ultrasound (LIPUS) may noninvasively enhance intratumoral delivery of radiopharmaceuticals, but clinical data are scarce. The authors prospectively evaluated whether adding LIPUS to prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) improves uptake and outcomes in metastatic prostate cancer while maintaining safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 42 men with PSMA PET-positive metastatic prostate cancer received up to six cycles of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-617. Before each infusion, LIPUS (1 MHz, 0.5\u20132.0 W\/cm\n                      <jats:sup>2<\/jats:sup>\n                      , 10 min) was applied to one dominant metastasis. Baseline and postcycle-1 PSMA PET\/CT measured percent change in SUV\n                      <jats:sub>max<\/jats:sub>\n                      (\u0394SUV\n                      <jats:sub>max<\/jats:sub>\n                      ) for the sonicated lesion versus a matched nonsonicated reference lesion. Patients were classified as high (\u0394SUV\n                      <jats:sub>max<\/jats:sub>\n                      \u226520%) or low enhancement. Prostate-specific antigen (PSA) response, progression-free survival (PFS), and toxicity were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      LIPUS was feasible in all patients without treatment interruptions. Sonicated lesions showed higher uptake (median \u0394SUV\n                      <jats:sub>max<\/jats:sub>\n                      + 32%) than reference lesions (+3%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001). High-enhancement patients had more PSA_50 responses (71% vs. 33%) and longer PFS (11.5 vs. 5.3 months; hazard ratio 0.35). Adverse events were mainly Grades 1\u20132 local discomfort and typical\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA toxicities; no Grade \u22653 LIPUS-related events occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>US-enhanced RLT appears safe and can increase intratumoral radiotracer uptake, translating into improved biochemical control and PFS in metastatic prostate cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10849785261431192","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:44:42Z","timestamp":1775886282000},"page":"941-951","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Evaluation of Ultrasound-Enhanced Radiotracer Uptake for Radioligand Therapy in Metastatic Prostate Cancer"],"prefix":"10.1177","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8525-1572","authenticated-orcid":false,"given":"Yangbing","family":"Liang","sequence":"first","affiliation":[{"name":"Guigang City People\u2019s Hospital, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingguo","family":"Wu","sequence":"additional","affiliation":[{"name":"Guigang City People\u2019s Hospital, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Liang","sequence":"additional","affiliation":[{"name":"Guigang City People\u2019s Hospital, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanchu","family":"Ji","sequence":"additional","affiliation":[{"name":"Guigang City People\u2019s Hospital, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2016.02.04"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/10849785251371491"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jum.16355"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2023.01.014"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.34133\/bmef.0080"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.10.007"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.161299"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/cr500171e"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263196"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.04.002"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.13740"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3670-z"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10071050"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785261431192","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10849785261431192","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785261431192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:28:11Z","timestamp":1793204891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10849785261431192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,12,1]]}},"alternative-id":["10.1177\/10849785261431192"],"URL":"https:\/\/doi.org\/10.1177\/10849785261431192","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]}}}